SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-051485
Filing Date
2023-11-06
Accepted
2023-11-06 06:06:32
Documents
14
Period of Report
2023-11-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20009756x14_8k.htm   iXBRL 8-K 28177
2 EXHIBIT 99.1 ny20009756x14_ex99-1.htm EX-99.1 26544
6 logo_gni.jpg GRAPHIC 5708
  Complete submission text file 0001140361-23-051485.txt   204338

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gyre-20231106.xsd EX-101.SCH 3907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20231106_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20231106_pre.xml EX-101.PRE 16072
8 EXTRACTED XBRL INSTANCE DOCUMENT ny20009756x14_8k_htm.xml XML 4205
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 250 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 250 SAN DIEGO CA 92130 650-266-8674
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

IRS No.: 562020050 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 231377994
SIC: 2834 Pharmaceutical Preparations